A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated‐interferon alpha

• Published in: Hepatology (Baltimore, Md.) Vol. 66; no. 4; pp. 1058 - 1066
• Main Authors: Cao, Zhenhuan, Liu, Yali, Ma, Lina, Lu, Junfeng, Jin, Yi, Ren, Shan, He, Zhimin, Shen, Chengli, Chen, Xinyue
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health, Inc 01.10.2017
• Subjects: Adefovir; Adefovir dipivoxil; Adult; Alanine; Alanine transaminase; Antigens; Antiviral Agents - therapeutic use; Carrier State - blood; Carrier State - drug therapy; Deoxyribonucleic acid; DNA; Feasibility Studies; Female; Hepatitis; Hepatitis B; Hepatitis B surface antigen; Hepatitis B Surface Antigens - blood; Hepatitis B, Chronic - blood; Hepatitis B, Chronic - drug therapy; Hepatology; Humans; Interferon; Interferon-alpha - therapeutic use; Male; Middle Aged; Polyethylene glycol; Polyethylene Glycols - therapeutic use; Recombinant Proteins - therapeutic use; Seroconversion; α-Interferon

Hepatitis B surface antigen (HBsAg) clearance represents a clinical cure, although the clearance rate is extremely low. The aim of this study was to evaluate the feasibility and safety profiles of pegylated‐interferon α‐2a (PEG‐IFNα‐2a) as a therapeutic option for inactive HBsAg carriers. There were...